Is amyris a good stock to buy?
Amyris has received a consensus rating of Buy.
Why is Amyris stock dropping?
While the major catalyst for the stock’s decline is the company’s uninspiring third-quarter 2021 earnings report, shareholders are also likely hitting the sell button in response to the company’s capital raise as well as Wall Street’s unfavorable take on the stock.
Is Amrs a buy?
Out of 6 analysts, 3 (50%) are recommending AMRS as a Strong Buy, 3 (50%) are recommending AMRS as a Buy, 0 (0%) are recommending AMRS as a Hold, 0 (0%) are recommending AMRS as a Sell, and 0 (0%) are recommending AMRS as a Strong Sell. What is AMRS’s earnings growth forecast for 2021-2023?
What does Amyris Inc do?
Amyris, Inc. produces and distributes chemical products. The Company serves the specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals markets.
Who owns Amyris stock?
Top 10 Owners of Amyris Inc
| Stockholder | Stake | Shares owned |
|---|---|---|
| The Vanguard Group, Inc. | 5.65% | 17,419,409 |
| BlackRock Fund Advisors | 3.96% | 12,206,539 |
| Farallon Capital Management LLC | 3.80% | 11,718,925 |
| BlackRock Advisors LLC | 3.45% | 10,621,946 |
Is Amrs overvalued?
The stock of Amyris (NAS:AMRS, 30-year Financials) is estimated to be significantly overvalued, according to GuruFocus Value calculation. At its current price of $19.88 per share and the market cap of $5.2 billion, Amyris stock is estimated to be significantly overvalued.
Will Amyris stock go back up?
Will Amyris stock price grow / rise / go up? Yes. The AMRS stock price can go up from 5.590 USD to 5.860 USD in one year.
Is Ginkgo Bioworks publicly traded?
Boston-based Ginkgo Bioworks began trading on the New York Stock Exchange on Friday, becoming the latest company to close a SPAC merger and go public. Shares opened at $11.15 apiece under ticker symbol “DNA,” giving the five-time CNBC Disruptor 50 company a market cap of nearly $2.5 billion.
Who owns Amyris Inc?
Amyris (company)
| Type | Public |
|---|---|
| Founded | 2003 |
| Headquarters | Emeryville, California, USA |
| Key people | John G. Melo (CEO) Eduardo Alvarez (COO) Han Kieftenbeld (CFO) Nicole Kelsey (Gen.Counsel & Secretary) |
| Brands | Biossance, Pipette and Purecane |
Who owns AMRS stock?
What is the long range forecast for AMRS stock?
Amyris Inc quote is equal to 5.590 USD at 2021-12-24. Based on our forecasts, a long-term increase is expected, the “AMRS” stock price prognosis for 2026-12-16 is 8.788 USD. With a 5-year investment, the revenue is expected to be around +57.21%. Your current $100 investment may be up to $157.21 in 2026.